Patients with ATTR-PN have a high rate of comorbidities and substantial direct healthcare and economic burdens, a study found.

In this essay, we will explore the symptoms of ATTR-CM and the five treatment options available for the heart condition.

Alnylam’s (ALNY) treatment of transthyretin-mediated amyloidosis, or ATTR amyloidosis, was granted FDA orphan designation, according to a post ...

Patients with combined diagnoses of ATTR-CM and aortic stenosis were at an increased risk of hospitalization and death, a study found.

Alnylam Pharmaceuticals (NASDAQ:ALNY), with a market capitalization of $35.4 billion, has emerged as a leading player in the RNA interference (RNAi) therapeutics space, with a particular focus on ...

Insights into the structures could lead to improved treatment strategies for transthyretin amyloidosis, a progressive, fatal disease in men.

The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion. While healthy transthyretin moves ...

The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion. While healthy ...

Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), a leader in RNA interference (RNAi) therapeutics, stands at a pivotal juncture as it seeks to capitalize on the burgeoning market for ...

Intellia downgraded to market perform at Morgan Stanley on concerns for ATTR-CM candidate nexiguran ziclumeran. Read more ...